Recombinant technology (Convacell)

Convacell® was created on the platform of a subunit vaccine based on the recombinant N protein of the SARS-CoV-2 virus.

Subunit vaccines contain viral proteins and their fragments necessary to stimulate the immune response, which are obtained by in vitro expression of genetically engineered constructs.

Subunit vaccines do not contain the entire pathogen, unlike live attenuated or inactivated vaccines.

Since the vaccine does not contain "live" components of the pathogen, there is no risk of disease.

The technology platform based on recombinant proteins has been successfully used for many years to produce vaccines and other pharmaceutical products against a wide range of different diseases. To date, clinical trials are carried out around the world for more than 1,000 different medicinal products, including recombinant ones.

The recombinant N protein of the SARS-CoV-2 virus is obtained using Escherichia coli, one of the most studied microorganisms in science. It is used to obtain thousands of different safe and effective proteins daily for various applications.

Developer’s website (SPbSRIVS)